Evidence map›Paper›PMID 41515468›Full record

ArticleMolecules (Basel, Switzerland)2026

{Zn

Lora Dyakova, Tanya Zhivkova, Abedulkadir Abudalleh, Daniela C Culita, Teodora Mocanu, Augustin M Madalan, Anamaria Hanganu, Gabriela Marinescu, Emanuil Naydenov, Radostina Alexandrova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lora DyakovaInstitute of Neurobiology, Bulgarian Academy of Sciences, Acad. Georgi Bonchev Str., Bl. 23, 1113 Sofia, Bulgaria.ORCID 0000-0003-1062-299X
Tanya ZhivkovaInstitute of Experimental Morphology, Pathology and Anthropology with Museum, Bulgarian Academy of Sciences, Acad. Georgi Bonchev Str., Bl. 25, 1113 Sofia, Bulgaria.ORCID 0000-0002-6494-8744
Abedulkadir AbudallehInstitute of Experimental Morphology, Pathology and Anthropology with Museum, Bulgarian Academy of Sciences, Acad. Georgi Bonchev Str., Bl. 25, 1113 Sofia, Bulgaria.ORCID 0000-0002-4705-8176
Daniela C CulitaIlie Murgulescu Institute of Physical Chemistry, Romanian Academy, 202 Splaiul Independentei, 060021 Bucharest, Romania.ORCID 0000-0001-9289-5443
Teodora MocanuIlie Murgulescu Institute of Physical Chemistry, Romanian Academy, 202 Splaiul Independentei, 060021 Bucharest, Romania.ORCID 0000-0002-2190-4696
Augustin M MadalanDepartment of Inorganic Chemistry, Organic Chemistry, Biochemistry and Catalysis, Faculty of Chemistry, University of Bucharest, 90-92 Panduri St., 050663 Bucharest, Romania.
Anamaria HanganuDepartment of Inorganic Chemistry, Organic Chemistry, Biochemistry and Catalysis, Faculty of Chemistry, University of Bucharest, 90-92 Panduri St., 050663 Bucharest, Romania.ORCID 0000-0002-0433-752X
Gabriela MarinescuIlie Murgulescu Institute of Physical Chemistry, Romanian Academy, 202 Splaiul Independentei, 060021 Bucharest, Romania.ORCID 0000-0002-3469-2442
Emanuil NaydenovDepartment of Neurosurgery, University Hospital St. Ivan Rilski, Blvd. "Acad. Ivan Geshov" 15, 1113 Sofia, Bulgaria.
Radostina AlexandrovaInstitute of Experimental Morphology, Pathology and Anthropology with Museum, Bulgarian Academy of Sciences, Acad. Georgi Bonchev Str., Bl. 25, 1113 Sofia, Bulgaria.ORCID 0000-0002-7699-6479

Funding

Bulgarian Science Fund КП-06-М61/3
6 · The paper itself

Abstract

The challenges of glioblastoma multiforme treatment are related to limitations in tumor removal surgery, its high heterogeneity and aggressiveness, development of resistance to standard therapy, the blood-brain barrier, and the side and toxic effects of the conventional antitumor agents used in clinical practice. Although new treatment strategies continue to emerge, progress remains slow and has not resulted in substantial improvements in patient survival. The main goal of research in recent years has been aimed at developing ways to deal with all these challenges. One of the ways to improve the control of glioblastomas is the introduction of effective new antitumor agents. Metal complexes represent a particularly promising class of compounds in this context. This is why the aim of this study was to assess the effects of six homo- and heterometallic coordination compounds bearing Schiff base ligands-[Zn

Indexed as

Antineoplastic AgentsCoordination ComplexesGlioblastomaZincCell Line, TumorCell ProliferationCell SurvivalHumansLigandsSchiff BasesAntineoplastic AgentsCoordination ComplexesLigandsSchiff BasesZinccytotoxic/antiproliferative activityglioblastoma multiformeZn(II)Au(I) heterometallic complexesZn(II) homometallic complexes

Identifiers

PMID41515468
PMCPMC12787429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.